Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Why Geron Corporation Shares Jumped

Watch stocks you care about

The single, easiest way to keep track of all the stocks that matter...

Your own personalized stock watchlist!

It's a 100% FREE Motley Fool service...

Click Here Now

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of Geron (NASDAQ: GERN  ) , a clinical-stage biopharmaceutical company focused on developing therapies to treat various types of cancer, jumped as much as 18% after an encouraging study by the Mayo Clinic demonstrated the effectiveness of Geron's experimental myelofibrosis drug, imetelstat.

So what: According to Bloomberg, the Mayo Clinic study involved 22 myelofibrosis patients who were studied for at least six months. The study notes that five patients achieved a partial or complete remission, while 41% of patients overall responded to the therapy. What's really exciting about this study, despite it being arguably small, is that complete responses in treating myelofibrosis are extremely rare, signaling the potential benefit that imetelstat could bring to patients.

Now what: I certainly won't take anything away from the Mayo Clinic's published results, but I continue to feel that Geron shareholders could be playing with fire here. At the moment for Geron, it's imetelstat or bust. This isn't to say that imetelstat hasn't delivered in clinical trials thus far (because it has), but I would point out that one drug over two clinical indications isn't a very diverse pipeline. I would contend that much of imetelstat's positive news of late has been baked into Geron's share price, and it wouldn't take much to knock Geron off its high horse if something didn't go its way with its lead drug. My suggestion would be to wait for a significant pullback or late-stage data to stream in before we get too excited about Geron's prospects.

This is the growth opportunity you won't want to miss
Geron has certainly delivered an impressive return to shareholders in 2013, but over the long run it may not be able to hold a candle to this incredible tech stock -- which is growing twice as fast as Google and Facebook, and more than three times as fast as and Apple. Watch our jaw-dropping investor alert video today to find out why The Motley Fool's chief technology officer is putting $117,238 of his own money on the table, and why he's so confident this company will be a huge winner in 2013 and beyond. Just click here to watch!

Read/Post Comments (1) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On December 08, 2013, at 6:17 PM, leviek wrote:

    With all due respect, this is simply the worst advice anyone familiar with the situation can give.

    Waiting to see if Imetelstat works is ridiculous and simply points to the fact the author has no knowledge, or incomplete knowledge, of the telomerase inhibitor drug, Imetelstat.

    Waiting for what, I might ask? The wait you talk about would have already cost a 500% move in the last few months. I suppose, without understanding the logic behind Geron's Imetelstat platform, one can wait for a 1000% move and the maybe decide they have enough information.

    Check your resources and look at the logic. Motley Fool is being completely and foolishly (excuse the pun) illogical. Imetelstat works: however, the extent of which can go from a modifying effect of myelofibrosis up to a cure. Additional positive outcomes may occur as more information is gathered over the next few years.

    The Motley Fool statements are absurd!!!!

Add your comment.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2755505, ~/Articles/ArticleHandler.aspx, 9/25/2016 10:15:56 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 1 day ago Sponsored by:
DOW 18,261.45 -131.01 -0.71%
S&P 500 2,164.69 -12.49 -0.57%
NASD 5,305.75 -33.78 -0.63%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/23/2016 4:00 PM
GERN $2.20 Down -0.02 -0.90%
Geron CAPS Rating: ***